This study analyzed the distribution of an idiotype, B3-Id, in patients with active SLE, classified according to organ involvement, normal controls, and other autoimmune rheumatic diseases. A polyclonal anti-idiotype was raised by immunizing a rabbit with a monoclonal IgG anti-double-stranded (ds) DNA antibody, B3, generated from a patient with SLE who had active arthritis. The idiotype is present on the X chain and is at or near the binding site for double-stranded DNA. The X chain, which was characterized by nucleotide sequencing, was 90% homologous to the VX2.1 germline, which is known to be involved in coding for nephritogenic anti-DNA antibodies carrying the 8.12 idiotype. There were four changes to positively charged amino acids, known to be involved in DNA binding, in the complementarity determining regions of B3 X chain compared with a non-DNA binding, 8.12 positive antibody, PVll. Only one change to a positively charged amino acid occurs in the heavy chain of B3, which is 93.5% homologous to VH-26.
Introduction
Immunoglobulin idiotypes are phenotypic markers ofthe variable genes used to encode immunoglobulin molecules. They are identified by anti-idiotypic antibodies. In the past decade, more than 20 apparently different DNA antibody idiotypes have been identified (reviewed in reference 1), and there have been several attempts to correlate those present in the serum of SLE patients with different serological or clinical manifestations ( 1, 2) . Idiotype analysis has been based on three different methodologies. The first has utilized anti-idiotypic antibodies to idiotypes first identified on IgM human monoclonal anti-DNA antibodies that may not represent the pathogenic antibodies present in SLE. The second method has been to extract DNA binding antibodies from the sera and to use this heterogeneous material to produce anti-idiotypes. Ifthis latter approach is used, analysis ofthe idiotype structure involves generation of monoclonal antibodies bearing the particular idiotype and may identify idiotypes that are not confined to one variable gene (3) . The third method involves identifying idiotypes on mouse anti-DNA antibodies which are then found to be expressed on human antibodies (4) .
Whichever method has been used few ofthe DNA antibody idiotypes have shown a clear cut association with disease activity. Among those whose levels did appear to fluctuate in this manner were the 16/6 and GN-2 idiotypes and the 9G4 idiotope (2, 5) . Lack ofcorrelation between levels ofidiotypes with different disease manifestations seen in SLE may be caused by the tendency of the investigators to use global score indices. Apart from problems ofdisease activity index validation, use of these indices may conceal important disease correlations within individual systems. Moreover, it is possible that different mechanisms are responsible for the activity in different organs or systems. In this study, we have utilized the British Isles Lupus Assessment Group (BILAG)' activity index that has been developed to overcome these problems (6) and thus enables the presence of anti-DNA idiotypes to be related to the full range of individual disease manifestations.
The analysis of DNA antibody idiotypes has not always differentiated whether the idiotype is present on the IgG or IgM population. This is a potentially important distinction to make, since idiotype regulation of IgM antibodies may be different from their IgG counterparts, which are more likely to be pathogenic, at least in lupus nephritis (7) . Moreover, the presence of an idiotype exclusively on the IgG population may indicate an idiotype generated by somatic mutation.
We have reported the production ofa monoclonal IgG anti-DNA antibody, B3, from a patient with active SLE (8) . This antibody has been used to generate an anti-idiotypic antibody that recognizes a common idiotype (Id) designated B3-Id. We now present the serologic and genetic characterization of Methods 101 patients with SLE were studied (mean age = 43±11.6; female/ male (F/M) = 92:3). Each of the SLE patients met the American Rheumatism Association's revised criteria for the classification of the disease (9) . Disease activity was assessed by the BILAG activity index (6) . This index, based on the principle of the physician's intention to treat the disease, assesses the activity of the disease in eight major organs or systems (10) . From this assessment, scores are generated ranging from A (most active) to E (no activity in that particular organ system). Only sera taken from patients when their disease was active (i.e., at least one A or B score) were studied (except for serial studies and when the B3-Id level was high, see Results). Although not designed for this purpose, the BILAG index can be adapted to provide a global score, A = 9 points, B = 3, C = 1, D = 0, and E = 0, which has been validated against other global scores ( 11 ). The sera studied were taken from patients with active disease on a particular date in one of six systems; i.e., musculoskeletal (M/S), skin, renal, central nervous system (CNS), cardiovascular/respiratory (CVS/resp), and vascular. (A score of A in the musculoskeletal system implies either definite myositis or severe polyarthritis with loss of function only, whereas a score of B implies either definite synovitis or tendonitis only). There was considerable overlap in the BILAG scores between general and hematology and the other systems; there was no bias towards one particular system. Our intention was to analyze dates when only one system was active. Thus, ifon one particular date both M/S and CNS systems were active, this sample was excluded. In addition, a number of serum samples from idiotype-positive patients were studied when the disease was inactive and serial bleeds were assessed (see Results). The sera from 27 patients with rheumatoid arthritis (each ofwhom met the revised criteria of the American Rheumatism Association [12] ) (mean age = 57±13.4; F/M = 14:13), 20 patients with primary Sjbgren's syndrome (who fulfilled criteria for the disease [13] ) (mean age = 58±14.5; F/M = 15:5), 17 patients with idiopathic myositis (14) (mean age = 46±14.5; F:M 12:5), and 28 normal controls (mean age = 39±1 1; F/M = 19:9) were also examined.
Monoclonal antibody andproduction ofanti-idiotype. The production, purification and specificity of B3 has been described in detail elsewhere (8) . In brief, peripheral blood lymphocytes from a patient with active SLE were fused with the heteromyeloma CB-F7 (kind gift of Siegbert Jahn, Charite Hospital, Berlin). At the time of fusion this patient had severe polyarthritis, fatigue, mild chest pain, periungual erythema, and livedo reticularis. The BILAG scores were as follows: general, B; skin, C; neurological, D; M/S, A; CVS/resp, B; vascular, C; renal, E; haematology, A. B3 binds predominantly to double-stranded (ds) DNA, but also weakly to single-stranded (ss) DNA in solid phase, by ELISA. The antibody also binds to Crithidia. B3 was purified by passing the supernatant (serum free) over a protein G column (Pharmacia fine Chemicals, Piscataway, NJ) and eluting with 0.1 M glycine-HC1 buffer, pH 2.3. Polyclonal anti-idiotype sera were raised by immunization of rabbits with purified mAb B3 in incomplete Freund's adjuvant. Polyclonal anti-idiotypic serum was rendered idiotypic specific by extensive absorption over a human IgG/IgM-Sepharose 4B (Pharmacia Fine Chemicals) affinity column until no anti-human Ig activity was detectable by an Ig ELISA. The anti-idiotypic serum was further purified to remove irrelevant specificities by purification on a B3 Sepharose column followed by acid elution ofbound antibody. Control rabbit immunoglobulin was raised by injecting rabbits with incomplete Freund's adjuvant alone and removing the anti-Fc activity on a human IgG/IgM-Sepharose 4B affinity column until no anti-human Ig activity was detectable by ELISA.
Characterization ofanti-Id-B3
Competitive ELISA for idiotype expression. Using a previously described method (15) , rabbit anti-Id-B3 reagent (at a concentration previously determined to give 50% maximal binding of anti-Id-B3 to mAb B3, that is 50 ng/ml) was incubated with varying concentrations of B3, pooled IgG, or a control mAb IgG for 1 h at 370C. Reaction mixtures were then added to mAb B3-coated wells (1 ug/ml) for 1 h at 370C. A mouse monoclonal anti-rabbit alkaline phosphatase conjugate (Sigma Immunochemicals, St. Louis, MO) was used to determine the amount of anti-idiotype bound.
Competitive ELISA for antigen binding site idiotype expression. The method has been described ( 15 ) . Reaction mixtures of mAb at the same concentration and antigen at varying concentrations, in this case, calfthymus dsDNA, ssDNA, and RNA, were incubated for 1 h at 370C before being transferred to anti-Id-coated wells for 1 h at 370C. The amount of human monoclonal antibody that had bound to the plate was determined by using an anti-human alkaline phosphatase conjugate (Sigma Immunochemicals).
Determination ofposition ofId on light or heavy chain. To determine whether the B3-Id, as defined by the rabbit anti-B3-Id, was located on the heavy or light chain or was a conformational determinant, an immunoblotting technique in conjunction with SDS-PAGE was used as described elsewhere ( 16) . Briefly, mAb B3 monoclonal antibody was subjected to SDS-PAGE at a concentration of 1 Ug/ml per lane. Each lane was subjected to electrophoretic transfer and rabbit anti-X chain (Sigma Immunochemicals), rabbit anti-y chain (Sigma Immunochemicals), and the anti-Id were added to the separated lanes and binding was detected by a mouse monoclonal anti-rabbit alkaline phosphatase conjugate. To assess whether the binding of the anti-Id to B3 is exclusively directed towards the light chain, the concentration of mAb B3 was increased to 5 and 10 ,g/lml in the lanes, and three concentrations of the anti-Id (0.5, 2, and 10 ug/ml) were used. The intensities of the bands were analyzed by densitometry. Blots were scanned using a Hewlett-Packard Scanjet 2C scanner connected to an Apple MacIntosh IIfx running National Institutes ofHealth Image software with a gel-plotting macro.
ELISA for detection ofB3-Id on immunoglobulins in sera. A capture ELISAs was used to detect the B3-Id in human sera. A 96-well ELISA plate was divided into two. One half was coated with the affinity-purified anti-idiotype (concentration = 1 ug/ml), while the other halfof the plate was coated with the same concentration ofthe control rabbit immunoglobulin. Human sera (dilution 1 in 300, which gave low binding with the control rabbit immunoglobulin) was Results Characterization ofthe B3-Id. The specificity ofthe polyclonal anti-Id-B3 reagent for mAb B3 both in solid phase and fluid phase is shown in Fig 1. Anti-Id-B3 did not react with the control mAb or pooled IgG. Western blotting demonstrates that the B3-Id is present on the light chain, X, of the mAb (Fig.  2 a) . A semiquantitative analysis to determine whether the binding of the anti-idiotype to the monoclonal B3 was specific to the light chain was performed using Western blotting followed by densitometry (Fig. 2 b) . The binding of the anti-Id to the heavy chain was not significantly above that found with the normal rabbit serum at the highest concentration of B3 and anti-Id. Therefore, Id is almost certainly confined to the light chain. By inhibition ELISA, dsDNA but not ssDNA or RNA blocked the binding of B3 to the anti-Id demonstrating that the Id is at, or close to, the binding site of the mAb B3 (Fig. 3) . Therefore, the light chain is involved in the binding of B3 to dsDNA.
Expression ofthe B3-Id in sera. Based on tests of 28 healthy controls, the upper limit of normal of the idiotype expression on IgG was set at 34% (percent of the positive control) and the upper limit of normal ofthe idiotype expression on IgM was set at 22%. Fig. 4 shows the level of expression of the idiotype on IgG and IgM antibodies in the six different organ systems studug/ml Inhibitor ied in the SLE patients and in the other groups (Table I provides a summary). When present, the idiotype is expressed more frequently on IgG antibodies compared to IgM (P < 0.001 ) in SLE patients, whereas in the rheumatoid arthritis population, it is expressed more frequently on the IgM population (P < 0.05). Within the SLE cohort, the B3-Id was present more frequently in those patients with active (M/S) disease (42%) compared to patients with the other manifestations (P < 0.001 ). The serum of the 15 SLE patients that had significantly raised levels of B3-Id on IgG antibodies associated with active arthritis were also tested when their disease was inactive. Four of these patients' sera were also examined on a number of occasions (see serial studies below). Out of the other 11 shown). In addition, 10 patients with active arthritis that were B3-Id negative were also tested when their disease was inactive. In all cases, the sera was negative for the idiotype.
Out of the 35 patients with M/S disease, only three had myositis, all of whom were negative for the idiotype, the other patients had joint disease. There was no difference in the clinical expression of the joint disease between those patients who were idiotype-positive and idiotype-negative. 79 of the 101 SLE patients, in comparison with 16 out of 20 B3-Id positive patients, had anti-DNA antibodies, indicating that the antiidiotype did not select out patients whose serum bound DNA. The one rheumatoid arthritis patient that had the B3-Id on the IgG population had detectable anti-DNA antibodies by ELISA (though not by Crithidia immunofluorescence). One out of the six SLE patients with B3-Id on the IgM population had an erosive arthritis as well. The level ofexpression ofB3-Id on IgM was higher in the rheumatoid arthritis patients compared to the other groups.
Serial studies. Serial samples were taken from six idiotype positive patients to analyze the variation of the idiotype level over time. In the four patients with active arthritis, the level of B3 Id followed the musculoskeletal disease activity more closely than the overall disease activity without the musculoskeletal component (Kendall rank correlation P < 0.05, Fig.  5 ). The correlation between the B3 Id level and arthritis activity did not hold in the two patients who had raised idiotype levels in the serum taken at the time they had active skin disease (also shown in Fig. 5 ). The variation in idiotype levels in these two patients did not correlate with the variation in the BILAG score of any of the individual systems nor ofthe global score. When the disease was inactive, the idiotype was not found on IgM antibodies in any of the patients studied. The correlation of B3-Id with DNA binding seems to be less obvious.
The correlation between the idiotype level on IgG antibodies and the total IgG level was not significant (Fig. 6 a) . Fig. 6 b illustrates the lack of association between rheumatoid factor levels and the expression of the B3-Id on IgM antibodies in rheumatoid patients.
Serum absorption studies. After absorption of four individual SLE serum samples that were positive for DNA binding on a DNA-cellulose column, anti-DNA activity was unmeasurable. In the four patients studied between 46 and 64% of the B3-Id was present in the DNA binding fraction eluted from the column (individual data not shown). Thus, a sizable fraction of the DNA antibodies in the serum of these patients had the B3-Id.
Sequence analysis. The nucleotide sequence of the VX region of the IgG anti-dsDNA antibody B3 (Fig. 7 a) indicates that it has 90% homology with the germline gene VX 2.1 (23) , and 85% homology at the amino acid level Fig. 7 b. There is a total of 14 replacement mutations, 6 of which are in CDR3. The replacement to silent ratio in CDR3 ofthe light chain is 7, implying a possible antigen-driven mechanism. The JX region is unmutated JX2. A sequence comparison between B3 and PV I 1, an SLE-derived, IgM non-DNA binding mAb that carries the 8.12 Id (24) revealed a 96% homology at the nucleotide level and 89% homology at the amino acid level. There were four changes to positively charged amino acids (three arginines), known to be involved in DNA binding, in the CDRs of B3 X chain compared to none in the X chain of PV I 1. have 10 gg/ lane of B3. Lanes 1-3 and 7-9 were incubated with increasing concentrations of anti-Id (0.5 tg/ml, 2 ug/ml, and 10 fg/ ml); lanes 4 and 10 were incubated with 2 tag/ml of normal rabbit serum; and lanes 5 and 11, and 6 and 12 were incubated with anti-A and anti-y chain, respectively. There is no significant binding ofthe anti-Id to the heavy chain above that seen with the normal rabbit serum.
The nucleotide sequence ofthe heavy chain of B3 (Fig. 8 a) reveals that it has 93.5% homology with the germline gene segment VH26 (25) (26) . The PR4-Id derived from a patient with leprosy has been found to be expressed on IgG, IgM, and IgA antibodies in lupus patients, but no correlation was found between the IgG, IgA, and IgM PR4-Id levels and a variety of parameters in lupus patients including disease activity (27) . The (29) . The data presented here suggests that these observations might apply to the human X chain as well. PV 11 has been found to be negative for B3-Id (Ehrenstein, M., and B. Diamond, unpublished observation), and a comparison between the VL sequences of the two antibodies might indicate possible sites where the idiotype or part of the idiotype is situated. However, to localize the position of the idiotype, further epitope mapping and site-directed mutagenesis studies need to be performed.
The CDR1 of the K chain may be important in DNA binding of 31 idiotype-positive antibodies (30) . Indeed, Diamond and colleagues conclude that DNA binding by31-positive antibodies may be more a function of the light chain than the heavy chain. There are two important differences, however, between the 31-positive antibodies and B3. Firstly, the 31-positive K chains that bind DNA are more negatively charged than their germline counterparts and secondly, the heavy chains of the 31-positive antibodies show evidence for antigen selection, whereas the heavy chain of B3 shows a high homology to VH-26 without any evidence for antigen selection.
The germline gene VH-26, from which the nucleotide sequence of B3 is likely to be derived, encodes the 16/6 Id serum levels of which correlate with disease activity in patients with SLE (2). The replacement mutation of serine to arginine at position 54 is the only amino acid change likely to enhance DNA binding. In addition, the asparagine residue in CDR3, probably coded for by N addition, could also contribute to DNA binding. Arginine can form two hydrogen bonds with guanine in double-stranded DNA, and asparagine can hydrogen bond to adenine (31) .
Since IgG antibodies are more frequently, though not exclusively, associated with a secondary immune response where antigen stimulation plays an important part, evidence of antigen selection, that is increased replacement to silent mutations in the CDRs of the antibodies, would be expected to occur. Interestingly, only the replacement to silent mutation ratio in the CDR3 of B3 X chain, which is 7, indicates a possible antigen-driven mechanism (32) . Though the germline gene from this patient has not been determined, and thus these figures may not be entirely accurate, the link with the 8.12 idiotype does lend support to this conclusion. The may not only yield anti-DNA antibodies, but also specificities or particular idiotypes associated with arthritis. Moreover (33) . This provides a link between the elevation of the B3Id and the joint disease seen in SLE and rheumatoid arthritis. This link is potentially strengthened because the monoclonal B3 binds DNA/histone complexes, a feature not common to all DNA binding antibodies (8) . An alternative possibility to explain the presence of B3-Id on IgM antibodies in rheumatoid arthritis, although we do not favor it, is that the anti-idiotype is recognizing a slightly different epitope from that "seen" in patients with SLE.
Tissue studies have found the deposition of idiotypes such as 16/6, GN-2, and 9G4 in pathological lesions in kidneys and skin (26, 4, 5) , but it is rarely practical to obtain synovial biopsies ofpatients with SLE as there is usually little clinical indication. The B3-Id was not found in 10 renal biopsies of SLE patients (data not shown).
In summary, we have described the first anti-DNA antiidiotype derived from a human monoclonal anti-dsDNA antibody. This idiotype, when present on IgG antibodies, is associated with a proportion of SLE patients with active arthritis.
Moreover, it appears that this idiotype is expressed on IgM antibodies in some patients with rheumatoid arthritis. Sequence analysis implies that positively charged amino acids on the X chain may contribute to DNA binding.
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